Loading...
Researchers in Spain assessed the clinical benefits and safety of atezolizumab (a PD-L1 inhibitor) plus bevacizumab (a vascular endothelial growth factor inhibitor) in patients with advanced nonsquamous non–small-cell lung cancer (NSCLC) with tumor mutational burden of 10 or more mutations/megabase and no EGFR, ALK, STK11, MDM2, or ROS1 translocations.
In the multicenter, single-arm, open-label, phase 2 study, 38 patients were treated with 1200 mg atezolizumab plus 15 mg/kg bevacizumab once every 21 days until disease progression or unacceptable toxicity. Participants had a mean age of 63.7 years, all were white, and most were men (74%) and current or prior smokers (97%).
The rate of progression-free survival (PFS) at 12 months — the primary …